Europe's leading exchange for Life Sciences
SIX Swiss Exchange offers Swiss and foreign Life Sciences companies ideal conditions for raising capital.
As a proactive partner, SIX Swiss Exchange facilitates an efficient listing and access to financially
powerful Swiss and international investors and high liquidity.
Switzerland has the world's highest per capita density of bio and medtech companies. This is the
result of a long-standing and fruitful interactive relationship between the well-established Swiss
pharma, biotech and medtech industries and the country's financial institutions.
The centre for Life Sciences companies in Europe
SIX Swiss Exchange is Europe's leading exchange for Life Sciences companies, representing around 40%
of the European Life Sciences market capitalization across Europe's major stock exchanges. Switzerland's
capital-rich investor base, strong banking system and its leading industry know-how make up the country's
vibrant Life Sciences ecosystem. This enables companies to efficiently raise capital with the view
to drive scientific discovery through to market launch.
The most prominent stock markets in the Life Sciences sector in Europe*
The leading European exchange for Life Sciences IPOs
In 2000, Actelion was listed with SIX Swiss Exchange, and over time it became the largest European
pure-play listed biotech firm. The successful Actelion story ended with a USD 30 billion takeover
bid by Johnson&Johnson in 2017. But the next chapter opened with Idorsia - an R&D company which was
spun off as a contribution-in-kind to the former shareholders of Actelion. Idorsia listed on
SIX Swiss Exchange in June 2017 with a market capitalization of about CHF 1.5 billion as of the
closing on the first trading day. In addition, the most prominent global pharmaceutical players,
Novartis and Roche, feature among the issuer base of SIX Swiss Exchange and lay the foundations for
a well-diversified peer group whose strong appeal reaches far beyond Switzerland's borders.
In addition to Newron Pharmaceuticals and Cosmo Pharmaceuticals, Cassiopea opted for a cross-border
listing on SIX Swiss Exchange in 2015. It therefore comes as no surprise that SIX Swiss Exchange
ranks among Europe's most important Life Sciences listing locations.
High profile among investors, analysts and media
SIX Swiss Exchange listed Life Sciences companies benefit from outstanding visibility among investors and the media, as
well as broad coverage by more than 100 analysts specializing in this sector. Extensive sector-specific
expertise enable companies to expect a stable market environment and an attractive valuation.
Find out more about the advantages of Switzerland as a Life Sciences hub and the added value of a listing
on SIX Swiss Exchange in our factsheet[pdf].